Clinical Trials List
2017-05-01 - 2025-12-31
Phase III
Recruiting3
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yih-Jyh Lin Division of General Surgery
- Liu Yi-Sheng Division of Radiology
- Chiu Hung Chiu Digestive System Department
- Pin-Nan Cheng Digestive System Department
- 邱彥程 Digestive System Department
- 簡世杰 Digestive System Department
- 吳毅晉 Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hung-Wei Wang Digestive System Department
- 陳昇弘 Digestive System Department
- 蘇文邦 Digestive System Department
- Hung-Yao Chen Digestive System Department
- Po-Heng Chuang Digestive System Department
- Cheng-Yuan Peng Digestive System Department
- Wei-Fan Hsu Digestive System Department
- Hsueh-Chou Lai Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
16 participants
-
Global
450 participants
